AGTX 10-K & 10-Q changes, risk factors and insider trading
Agentix Corp. · OTC · Biological Products, (No Diagnostic Substances) · CIK 1603345 · All filings on SEC.gov
At a glance
What changed in the latest 10-K
Risk Factors
As a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information called for by this Item.
No wording changes found in this section.
Full comparison: every changed paragraph (0)
Management's Discussion & Analysis (MD&A)
Largest changes
For the year ended March 31,see in full comparison2025,2026, cash from financing was$100,00$110,450 versus$93,000$100,000 for our year ended March 31,2024.2025. Cash from financings during the year ended March 31,20252026 and 2025, respectively, consisted of $110,450 and $100,000 from loan proceeds received.Cash from financings during the year ended March 31, 2024 consisted of $163,000 from loan proceeds received offset by our payment of $70,000 on our loans.
“For the year ended March 31, 2025 and 2024, we received R&D credits totaling $0 and $198,371 related to our R&D efforts that occurred at our Agentix Australia Pty Ltd entity. We did not receive any R&D credits for the comparable period ended March 31, 2025.”see in full comparison
For the year ended March 31,see in full comparison2025,2026, general and administrative expenses were$69,898$68,072 as compared to$346,543$69,898 for our year ended March 31,2024,2025, a decrease of$276,645. The decrease was mainly related to a decrease in royalty fee we incurred related to patents in the prior period, compared to the prior period.$1,826.
“For the year ended March 31, 2025, professional fees were $262,366 as compared to $222,999 for the year ended March 31, 2024, an increase of $39,367. The Increase in professional fees mainly to an increase in accounting and consulting fees.”see in full comparison
For the year ended March 31,see in full comparison2025,2026, we incurred total research and development expenses of$180,987$125,079 as compared to$175,268$180,987 for our year ended March 31,2024,2025,anaincreasedecrease of$5,719.$55,908. Theincreasedecrease was mainly related to an increase in R&Dconsultingconsulting,costs.offset by a decrease in supplies and materials and patent maintenance.
“Subsequent to March 31, 2025, Gray’s Peak extended the due date of the Note (see Note 3) by six months. As such, the new maturity date is December 31, 2025.”see in full comparison
Full comparison: every changed paragraph (12)
For the year ended March 31, 2026, professional fees were $252,036 as compared to $262,366 for the year ended March 31, 2025, a decrease of $10,330.
For the year ended March 31, 2025, professional fees were $262,366 as compared to $222,999 for the year ended March 31, 2024, an increase of $39,367. The Increase in professional fees mainly to an increase in accounting and consulting fees.
For the year ended March 31, 2025,2026, we incurred total research and development expenses of $180,987$125,079 as compared to $175,268$180,987 for our year ended March 31, 2024,2025, ana increasedecrease of $5,719.$55,908. The increasedecrease was mainly related to an increase in R&D consultingconsulting, costs.offset by a decrease in supplies and materials and patent maintenance.
For the year ended March 31, 2025,2026, general and administrative expenses were $69,898$68,072 as compared to $346,543$69,898 for our year ended March 31, 2024,2025, a decrease of $276,645. The decrease was mainly related to a decrease in royalty fee we incurred related to patents in the prior period, compared to the prior period.$1,826.
For the year ended March 31, 2026, foreign exchange gain was $24,584 as compared to foreign exchange loss of $11,128 for the year ended March 31, 2025.
For the year ended March 31, 2025 and 2024, foreign exchange loss was $11,128 and $17,929, respectively.
For the year ended March 31, 20252026 and 2024,2025, interest expense, net was $42,669$80,106 and $21,034,$42,669, respectively. The net increase in interest expense related to our increase in loan activitybalances during the year ended March 31, 20252026 as compared to our year ended March 31, 2024.2025.
For the year ended March 31, 2025 and 2024, we received R&D credits totaling $0 and $198,371 related to our R&D efforts that occurred at our Agentix Australia Pty Ltd entity. We did not receive any R&D credits for the comparable period ended March 31, 2025.
For the year ended March 31, 2025,2026, cash from financing was $100,00$110,450 versus $93,000$100,000 for our year ended March 31, 2024.2025. Cash from financings during the year ended March 31, 20252026 and 2025, respectively, consisted of $110,450 and $100,000 from loan proceeds received. Cash from financings during the year ended March 31, 2024 consisted of $163,000 from loan proceeds received offset by our payment of $70,000 on our loans.
Our consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business. As reflected in our consolidated financial statements for the year ended March 31, 2025,2026, we had an accumulated deficit,deficit of $7,007,164, we did not incur any revenue and we had a net loss along with negative cash generated from our operations. In addition, we owe our vendors and related parties $3,204,523$3,596,282 as of March 31, 2025.2026. Although, on January 15, 2023 and June 15, 2023, we entered into two separate Mezzanine Secured Note (“Notes”) in the principal amount up to $200,000 and $500,000, respectively, with Gray’s Peak Private Credit LLC (see Note 3 to the consolidated financial statements), the debt maturity of these Notes is short term. These factors raise substantial doubt about our ability to continue as a going concern.
Subsequent to March 31, 2025, Gray’s Peak extended the due date of the Note (see Note 3) by six months. As such, the new maturity date is December 31, 2025.
In accordance with ASC 855, we have analyzed our operations subsequent to March 31, 20252026 through the date these financial statements were issued, and have determined that we don’tdo not have any other material subsequent events to disclose in these financial statements.
What changed in the latest 10-Q
Risk Factors
As a smaller reporting company (as defined in Rule 12b-2 of the Exchange Act), we are not required to provide the information called for by this Item 1A.
No wording changes found in this section.
Full comparison: every changed paragraph (0)
Management's Discussion & Analysis (MD&A)
Removed heading “Nine Months Ended December 31, 2025 as compared to Nine Months Ended December 31, 2024:”
Largest changes
“Nine Months Ended December 31, 2025 as compared to Nine Months Ended December 31, 2024:”see in full comparison
The following information should be read in conjunction with (i) the unaudited consolidated financial statements of Agentix Corp., a Nevada corporation (the “Company”), andsee in full comparisondevelopment stage company, andthe notes thereto appearing elsewhere in this Form 10-Qtogether withand (ii) the more detailed business information andtheauditedMarch 31, 2025 auditedconsolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K(File No. 000-55383;for the“Formfiscal10-K”),yearasendedfiledMarchwith31,the Securities and Exchange Commission.2026. Statements in this section and elsewhere in this Form 10-Q that are not statements of historical or current fact constitute“forward-looking”statements.
Three Months Endedsee in full comparisonDecemberJune31,30,20252026 as compared to Three Months EndedDecemberJune31,30,20242025:
Our unaudited consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, realization ofsee in full comparisonassets,assets and liquidation of liabilities in the normal course of business. As reflected in our unaudited consolidated financial statements for theninethree months endedDecemberJune31,30,2025,2026, we had an accumulateddeficit,deficitweofhad$7,124,838, a net lossalongofwith$117,674,negativenet cashgeneratedusedfrominouroperatingoperationsactivitiesandofwe have a$26,372, negative workingcapital.capitalInofaddition,$3,713,793,wecashoweofour vendors$38, andrelatedtotalpartiescurrent$3,504,397liabilities of $3,713,831 as ofDecember 31, 2025. Although, on January 15, 2023 andJune15,30,2023, we entered into two separate Mezzanine Secured Note (“Notes”) in the principal amount up to $200,000 and $500,000, respectively, with Gray’s Peak Private Credit LLC (see Note 3 to the unaudited consolidated financial statements), the debt maturity of these Notes is short term.2026. These factors raise substantial doubt about our ability to continue as a going concern.
“As a result, net loss for the three months ended December 31, 2025 was $78,595, as compared to a net loss of $143,894 for the three months ended December 31, 2024. Other comprehensive loss for the three months ended December 31, 2025 included a favorable foreign currency translation adjustment of $1,367 (compared to an unfavorable $63,927 in the prior-year period), resulting in total comprehensive loss of $79,962 versus $79,967 in the prior-year period.”see in full comparison
As a result, net loss for thesee in full comparisonninethree months endedDecemberJune31,30,20252026 was$408,526, as$117,674 comparedtowith a net loss of$385,280$185,824 for theninethree months endedDecemberJune31,30,2024.2025. Other comprehensive loss for theninethree months endedDecemberJune31,30,20252026 included an unfavorable foreign currency translation adjustment of$14,775$608,(comparedtowithanaunfavorablefavorable$28,759adjustmentinof $18,307 for the prior-yearperiod),period, resulting in total comprehensive loss of$393,751$118,282versusand$356,521$167,517,in the prior-year period.respectively.
Full comparison: every changed paragraph (23)
The following information should be read in conjunction with (i) the unaudited consolidated financial statements of Agentix Corp., a Nevada corporation (the “Company”), and development stage company, and the notes thereto appearing elsewhere in this Form 10-Q together withand (ii) the more detailed business information and theaudited March 31, 2025 auditedconsolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K (File No. 000-55383;for the “Formfiscal 10-K”),year asended filedMarch with31, the Securities and Exchange Commission.2026. Statements in this section and elsewhere in this Form 10-Q that are not statements of historical or current fact constitute “forward-looking” statements.
Our unaudited consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and with the rules and regulations of the SEC applicable to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are,that, in the opinion of management, are necessary tofor a fair statement of the results for the interim periods presented. Unaudited interim results are not necessarily indicative of the results for the full fiscal year. These financial statements should be read in conjunction with ourthe audited consolidated financial statements for the reporting period ended March 31, 2025 and notes thereto containedincluded in our Annual Report on Form 10-K.10-K for the fiscal year ended March 31, 2026.
Three Months Ended DecemberJune 31,30, 20252026 as compared to Three Months Ended DecemberJune 31,30, 20242025:
We recorded no revenuesrevenue during the three months ended DecemberJune 31,30, 20252026 and 2024.2025.
For the three months ended DecemberJune 31,30, 2025,2026, professional fees were $50,678 as$62,084 compared towith $56,632$82,625 for the three months ended DecemberJune 31,30, 2024,2025, a decrease of $5,954.$20,541. The increase in professional feesdecrease was mainlyprimarily due to higherlower accountingprofessional andservice consultingcosts fees.during the current period.
For the three months ended DecemberJune 31,30, 2025,2026, research and development expenses were $0,$16,635 compared towith $23,287$100,000 for the same period in 2024,2025, reflecting ana decrease of $23,287.$83,365. The decrease was mainly related to reducedlower R&Dresearch consultingand costs.development activity during the current period.
For the three months ended DecemberJune 31,30, 2025,2026, general and administrative expenses were $16,785 as compared towith $16,896$17,717 for the three months ended DecemberJune 31,30, 2024,2025, a slight decrease of $111.$932, Thereflecting decrease was primarily related toslightly lower software and other administrative costs.
ForThe theCompany threerecorded months ended December 31, 2025,no foreign exchange gain was $2,672 compared to aor loss of $35,784 for the three months ended DecemberJune 31,30, 2024,2026, compared with a $38,456foreign lessexchange favorablegain of $15,140 for the three months ended June 30, 2025, a $15,140 unfavorable variance due primarily to fluctuations in currency exchange rates.
For the three months ended December 31, 2025, interest expense, net was $13,804 as compared to $11,295 for the three months ended December 31, 2024. The increase of $2,509 related to higher average borrowings and related financing costs during the period.
For the three months ended December 31, 2025, other income was $0 (no comparable amount in the prior-year quarter).
As a result, net loss for the three months ended December 31, 2025 was $78,595, as compared to a net loss of $143,894 for the three months ended December 31, 2024. Other comprehensive loss for the three months ended December 31, 2025 included a favorable foreign currency translation adjustment of $1,367 (compared to an unfavorable $63,927 in the prior-year period), resulting in total comprehensive loss of $79,962 versus $79,967 in the prior-year period.
Nine Months Ended December 31, 2025 as compared to Nine Months Ended December 31, 2024:
We recorded no revenues during the nine months ended December 31, 2025 and 2024.
For the nine months ended December 31, 2025, professional fees were $214,536 as compared to $197,942 for the nine months ended December 31, 2024, an increase of $16,594. The increase in professional fees was mainly due to higher accounting, legal and consulting support.
For the nine months ended December 31, 2025, research and development expenses were $125,079 as compared to $90,638 for the same period in 2024, an increase of $34,441, primarily related to increased R&D consulting and project activity.
For the nine months ended December 31, 2025, general and administrative expenses were $51,287 as compared to $52,550 for the nine months ended December 31, 2024, a decrease of $1,263, reflecting cost controls and lower software and overhead expenses.
For the nine months ended December 31, 2025, foreign exchange gain was $20,961 compared to a loss of $15,376 for the nine months ended December 31, 2024, a $36,337 less favorable variance due primarily to currency fluctuations.
For the ninethree months ended DecemberJune 31,30, 2025,2026, interest expense, net was $59,189 as$22,170 compared towith $28,774$21,226 for the ninethree months ended DecemberJune 31,30, 2024,2025, an increase of $30,415,$944 related to higher average debt balances and related financingaccrued costs.interest.
For the three months ended June 30, 2026, other income was $0 compared with $20,604 for the three months ended June 30, 2025. The prior-year amount related to a gain on settlement of payables.
For the nine months ended December 31, 2025, other income was $20,604, consisting primarily of a gain recognized on the settlement of accounts payable (no comparable amount in the prior-year period).
As a result, net loss for the ninethree months ended DecemberJune 31,30, 20252026 was $408,526, as$117,674 compared towith a net loss of $385,280$185,824 for the ninethree months ended DecemberJune 31,30, 2024.2025. Other comprehensive loss for the ninethree months ended DecemberJune 31,30, 20252026 included an unfavorable foreign currency translation adjustment of $14,775$608, (compared towith ana unfavorablefavorable $28,759adjustment inof $18,307 for the prior-year period),period, resulting in total comprehensive loss of $393,751$118,282 versusand $356,521$167,517, in the prior-year period.respectively.
Our unaudited consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, realization of assets,assets and liquidation of liabilities in the normal course of business. As reflected in our unaudited consolidated financial statements for the ninethree months ended DecemberJune 31,30, 2025,2026, we had an accumulated deficit,deficit weof had$7,124,838, a net loss alongof with$117,674, negativenet cash generatedused fromin ouroperating operationsactivities andof we have a$26,372, negative working capital.capital Inof addition,$3,713,793, wecash oweof our vendors$38, and relatedtotal partiescurrent $3,504,397liabilities of $3,713,831 as of December 31, 2025. Although, on January 15, 2023 and June 15,30, 2023, we entered into two separate Mezzanine Secured Note (“Notes”) in the principal amount up to $200,000 and $500,000, respectively, with Gray’s Peak Private Credit LLC (see Note 3 to the unaudited consolidated financial statements), the debt maturity of these Notes is short term.2026. These factors raise substantial doubt about our ability to continue as a going concern.
In accordance with ASC 855, wethe haveCompany has analyzed ourits operations subsequent to DecemberJune 31,30, 20252026 through the date these financial statements were issued,issued and havehas determined that weit don’tdoes not have any other material subsequent events to disclose in these financial statements.
AGTX insider buying and selling (Form 4)
Since 2026-04-11, insiders reported open-market purchases in 0 Form 4 filings and open-market sales in 0 filings. Totals add up every open-market (code P and S) line in those filings, using the prices reported in the filings. Awards, option exercises, tax withholding and gifts are listed below but not counted.
No Form 4 stock transactions in this period.
Well-known investors holding AGTX (13F)
None of the 59 investors we track reported a position in their latest 13F.